Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $9.62

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given an average recommendation of “Reduce” by the ten analysts that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $9.6222.

Several analysts recently weighed in on YMAB shares. Truist Financial set a $8.60 price objective on Y-mAbs Therapeutics in a report on Tuesday, August 5th. HC Wainwright reaffirmed a “neutral” rating and set a $8.60 target price (down previously from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th. Cantor Fitzgerald set a $8.60 price target on Y-mAbs Therapeutics and gave the company a “neutral” rating in a report on Tuesday, August 5th. Oppenheimer downgraded Y-mAbs Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 5th. Finally, Brookline Capital Management downgraded shares of Y-mAbs Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $8.61 on Friday. The firm has a market capitalization of $391.24 million, a price-to-earnings ratio of -17.22 and a beta of 0.54. The company has a 50-day moving average of $8.57 and a 200 day moving average of $5.93. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.20. The business had revenue of $19.52 million for the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. On average, equities analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in shares of Y-mAbs Therapeutics by 4.8% in the first quarter. Rhumbline Advisers now owns 53,909 shares of the company’s stock valued at $239,000 after acquiring an additional 2,457 shares during the period. Jump Financial LLC boosted its stake in shares of Y-mAbs Therapeutics by 14.1% during the first quarter. Jump Financial LLC now owns 38,079 shares of the company’s stock valued at $169,000 after acquiring an additional 4,699 shares during the last quarter. CWM LLC grew its position in shares of Y-mAbs Therapeutics by 203.0% in the second quarter. CWM LLC now owns 7,121 shares of the company’s stock valued at $32,000 after purchasing an additional 4,771 shares during the period. Brooklyn Investment Group boosted its position in shares of Y-mAbs Therapeutics by 4,563.8% in the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock worth $26,000 after acquiring an additional 5,796 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Y-mAbs Therapeutics by 129.0% during the second quarter. Tower Research Capital LLC TRC now owns 11,494 shares of the company’s stock worth $52,000 after acquiring an additional 6,474 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.